Arcturus therapeutics reports fourth quarter and year end 2019 financial results

Arcturus therapeutics reports fourth quarter and year end 2019 financial results.q4 revenue $3.0 million versus refinitiv ibes estimate of $3.6 million.q4 loss per share $0.76.q4 earnings per share estimate $-0.53 -- refinitiv ibes data.arcturus therapeutics ltd - coronavirus vaccine program initiated.arcturus therapeutics ltd - ind filed for flagship program arct-810.arcturus therapeutics ltd - cash, cash equivalents, and investments totaled $71.4 million as of december 31, 2019.arcturus therapeutics ltd - company's current cash position is expected to be sufficient to support operations through q1 of 2021.
ARCT Ratings Summary
ARCT Quant Ranking